RxDoctor Payments Data

Sindhura Bandi, MD

Allergy & Immunology · Chicago, ILNPI 1891951208

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $5,504 of the $7,999 with a category attached, or 68.8%. AstraZeneca accounts for 71.4% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2023 at $5,613 and has fallen 94.6% since, to $301 in 2025.

$7,999in general payments, 2019–2025

Across 18 payments — averaging $444.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$6K
  • Alk-abello, Inc$2K
  • Blueprint Medicines Corporation$335
  • GSK$145
  • Genentech USA, Inc.$66
  • Aimmune Therapeutics, Inc.$17
  • plus $5 from 1 others

What the payments were for

  • Consulting fees$5,50469%
  • Speaking & faculty fees$1,40018%
  • Food & beverage$1,09514%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca4$5,712
Alk-abello, Inc6$1,719
Blueprint Medicines Corporation3$335
GSK2$145
Genentech USA, Inc.1$66
Aimmune Therapeutics, Inc.1$17
Bio Products Laboratory USA, Inc.1$5

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,999 in reported general payments places this provider in the 70th percentile of 161 allergy & immunology providers in Illinois.

See all allergy & immunology providers in Illinois

Medicare billing

Part B allowed, 2024
$19,561
Medicare patients
107
Services billed
198

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XolairOmalizumab107$398,270
Fasenra PenBenralizumab16$85,147
Dupixent PenDupilumab14$50,957
Advair HfaFluticasone Propion/Salmeterol15$6,036
Azelastine Hcl94$3,441
Epinephrine17$3,049
Arnuity ElliptaFluticasone Furoate12$2,518
Advair DiskusFluticasone Propion/Salmeterol12$2,238
Albuterol Sulfate HfaAlbuterol Sulfate54$1,631
Fluticasone Propionate77$1,144
Montelukast Sodium58$988
Ipratropium Bromide32$810
Dapsone13$538
Prednisone11$15

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKArnuity Ellipta$145$2,51812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 161 allergy & immunology providers in Illinois.

Other allergy & immunology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →